The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
Open accessAbstract
Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings. A dynamic HCV transmission model was parameterized to three chronic HCV prevalence settings: Edinburgh, UK (25%); Melbourne, Australia (50%); and Vancouver, Canada (65%). Using realistic scenarios of future DAAs (90% sustained viral response, 12 weeks duration, available 2015), we projected the treatment rates required to reduce chronic HCV prevalence by half or three-quarters within 15 years. Current HCV treatment rates may have a minimal impact on prevalence in Melbourne and Vancouver (<2% relative reductions) but could reduce prevalence by 26% in 15 years in Edinburgh. Prevalence could halve within 15 years with treatment scale-up to 15, 40, or 76 per 1,000 PWID annually in Edinburgh, Melbourne, or Vancouver, respectively (2-, 13-, and 15-fold increases, respectively). Scale-up to 22, 54, or 98 per 1,000 PWID annually could reduce prevalence by three-quarters within 15 years. Less impact occurs with delayed scale-up, higher baseline prevalence, or shorter average injecting duration. Results are insensitive to risk heterogeneity or restricting treatment to PWID on OST. At existing HCV drug costs, halving chronic prevalence would require annual treatment budgets of US $3.2 million in Edinburgh and approximately $50 million in Melbourne and Vancouver. Conclusion: Interferon-free DAAs could enable increased HCV treatment uptake among PWID, which could have a major preventative impact. However, treatment costs may limit scale-up, and should be addressed. (Hepatology 2013;58:1598–1609)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., & Gray, R. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421303 · Cited by 3,020
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Unicef, U. (2011) · Cited by 1,292
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Micallef, J. M., Kaldor, J. M., & Dore, G. J. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00651.x · Cited by 871
Self-citationNucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Mathers, B. M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R. P., Myers, B., Ambekar, A., & Strathdee, S. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60232-2 · Cited by 717
Self-citationThe Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007
Ly, K. N., Xing, J., Klevens, R. M., Jiles, R. B., Ward, J. W., & Holmberg, S. D. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00004 · Cited by 711
Wood, E., Kerr, T., Marshall, B. D. L., Li, K., Zhang, R., Hogg, R. S., Harrigan, P. R., & Montaner, J. S. G. (2009) · BMJ · doi:10.1136/bmj.b1649 · Cited by 342
Van Den Berg, C., Smit, C., Van Brussel, G., Coutinho, R., & Prins, M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01912.x · Cited by 316
Hagan, H., Pouget, E. R., & Des Jarlais, D. C. (2011) · Journal of Infectious Diseases · doi:10.1093/infdis/jir196 · Cited by 313
Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G. J., Goldberg, D. J., & Hellard, M. E. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit306 · Cited by 309
Self-citationCornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010) · BMJ · doi:10.1136/bmj.c5475 · Cited by 307
Self-citationTurner, K. M. E., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., May, M., Taylor, A., De Angelis, D., Cameron, S., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03515.x · Cited by 299
Self-citationExploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Poordad, F., Lawitz, E., Kowdley, K. V., Cohen, D. E., Podsadecki, T., Siggelkow, S., Heckaman, M., Larsen, L., Menon, R., Koev, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208809 · Cited by 285
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
Hellard, M., Sacks‐Davis, R., & Gold, J. (2009) · Clinical Infectious Diseases · doi:10.1086/600304 · Cited by 232
Self-citationMartin, N. K., Vickerman, P., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.029 · Cited by 230
Self-citationCost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations
Martin, N. K., Vickerman, P., Miners, A., Foster, G. R., Hutchinson, S. J., Goldberg, D. J., & Hickman, M. (2012) · Hepatology · doi:10.1002/hep.24656 · Cited by 221
Self-citationAustralian Drug Trends 2000: Findings of the Illicit Drug Reporting System (IDRS)
Topp, L., Darke, S. G., Bruno, R., FRY, C. L., Hargreaves, K., HUMENIUK, R. E., McAllister, R., O'Reilly, B., & Williams, P. R. (2001) · eCite Digital Repository (University of Tasmania) · Cited by 193
New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis
Liu, S., Cipriano, L. E., Holodniy, M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00005 · Cited by 192
Kimber, J., Copeland, L., Hickman, M., Macleod, J., McKenzie, J., De Angelis, D., & Robertson, J. R. (2010) · BMJ · doi:10.1136/bmj.c3172 · Cited by 189
Self-citationGrebely, J., Raffa, J. D., Lai, C., Krajden, M., Kerr, T., Fischer, B., & Tyndall, M. W. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01080.x · Cited by 171
Self-citationClinical guidelines on the management of hepatitis C
Booth, J. C. L., O'Grady, J., & Neuberger, J. (2001) · Gut · doi:10.1136/gut.49.suppl_1.i1 · Cited by 161
Vickerman, P. T., Martin, N. K., Turner, K., & Hickman, M. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03932.x · Cited by 147
Self-citationDimova, R. B., Zeremski, M., Jacobson, I. M., Hagan, H., Jarlais, D. C. D., & Talal, A. H. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis1007 · Cited by 134
Changes in Blood-borne Infection Risk Among Injection Drug Users
Mehta, S. H., Astemborski, J. A., Kirk, G. D., Strathdee, S. A., Nelson, K. E., Vlahov, D., & Thomas, D. L. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq112 · Cited by 133
Triphasic decline of hepatitis C virus RNA during antiviral therapy
Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2007) · Hepatology · doi:10.1002/hep.21657 · Cited by 131
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users
Aitken, C. K., Lewis, J., Tracy, S. L., Spelman, T., Bowden, D. S., Bharadwaj, M., Drummer, H. E., & Hellard, M. E. (2008) · Hepatology · doi:10.1002/hep.22534 · Cited by 129
Self-citationHigh hepatitis C incidence in new injecting drug users: a policy failure?
Maher, L., Li, J., Jalaludin, B. B., Chant, K. G., & Kaldor, J. M. (2007) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2007.00007.x · Cited by 122
Nosyk, B., Marsh, D. C., Sun, H., Schechter, M. T., & Anis, A. H. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.008 · Cited by 118
Grebely, J., Knight, E., Genoway, K. A., Viljoen, M., Khara, M., Elliott, D., Gallagher, L., Storms, M. M., Raffa, J. D., DeVlaming, S., et al. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a8c4c · Cited by 114
Self-citationBurns, L., Randall, D., Hall, W., Law, M. G., Butler, T. G., Bell, J. R., & Degenhardt, L. J. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02633.x · Cited by 94
Acute hepatitis C: diagnosis and management
Mondelli, M. U., Cerino, A., & Cividini, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.017 · Cited by 76
Estimating the National and Local Prevalence of Problem Drug Misuse in Scotland
Hay, G., Gannon, M., McKeganey, N., & Goldberg, D. (2005) · ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · Cited by 71
Self-citationLiu, L., Fisher, B. E., Thomas, D. L., Cox, A. L., & Ray, S. C. (2012) · Hepatology · doi:10.1002/hep.25575 · Cited by 71
Estimating the prevalence of ex-injecting drug use in the population
Sweeting, M. J., Angelis, D. D., Ades, A. E., & Hickman, M. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280208094704 · Cited by 66
Self-citationUnstable housing and hepatitis C incidence among injection drug users in a Canadian setting
Kim, C., Kerr, T. H., Li, K. K., Zhang, R., TYNDALL, M. W., Montaner, J. S. G., & Wood, E. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-270 · Cited by 65
HIV/AIDS in Vancouver, British Columbia: a growing epidemic
McInnes, C. W., Druyts, E., Harvard, S. S., Gilbert, M., TYNDALL, M. W., Lima, V. D., Wood, E., Montaner, J. S. G., & Hogg, R. S. (2009) · Harm Reduction Journal · doi:10.1186/1477-7517-6-5 · Cited by 52
Self-citationHickman, M., Hope, V. D., Coleman, B., et al. (2009) · Journal of Public Health · doi:10.1093/pubmed/fdp067 · Cited by 52
Self-citationStoove, M. A., Dietze, P., Aitken, C. K., & Jolley, D. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.006 · Cited by 48
Allen, E. J., Palmateer, N. E., Hutchinson, S. J., Cameron, S., Goldberg, D. J., & Taylor, A. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2012.07.006 · Cited by 40
Self-citationReferral for chronic hepatitis C treatment from a drug dependency treatment setting
Hallinan, R., Byrne, A., Agho, K., & Dore, G. J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.09.018 · Cited by 39
Self-citationVickerman, P. T., Martin, N. K., & Hickman, M. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.08.001 · Cited by 36
Self-citationKing, R., Bird, S. M., Hay, G., et al. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280208094701 · Cited by 35
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Public health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Self-citationWilliams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 602
Self-citation
Metadata
- Authors
- Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., & Hickman, M.
- Venue
- Hepatology
- Published
- 2013-11
- Volume
- 58
- Issue
- 5
- Pages
- 1598-1609
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2115399503
- Cited by
- 488
- References
- 47
- FWCI
- 31.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.